Successful treatment of thymoma-associated erythroid hypoplasia and thrombocytopenia with paclitaxel

respectively. The reticulocyte count reached 3%. Computed tomography of the chest showed a minimal response to chemotherapy. Two additional cycles of paclitaxel were given. The patient’s haematological values and disease have remained stable for 6 months. The best therapy for thymomaassociated cytopenia has not yet been established. We think that antitumour therapies may be effective as in other paraneoplastic syndromes. To our knowledge, this is the first report showing that paclitaxel may be beneficial in the treatment of thymoma-associated haematologic dyscrasias. The role of paclitaxel in the treatment of thymoma is unknown. On the basis of this case, we suggest that paclitaxel at 175 mg/m 2 every 3 weeks may be a promising chemotherapy for advanced or recurrent thymoma.